Overview

A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

Status:
Completed

Trial end date:
2021-04-14

Target enrollment:

Participant gender:

Summary

A phase 2 study in two parts (A & B) designed to evaluate the effect of MEDI0382 on Hepatic Glycogen Metabolism in subjects with Type 2 Diabetes Mellitus (T2DM). Approximately 20 subjects will be enrolled in Part A and approximately 30 subjects in Part B.

Phase:

Phase 2

Details

Lead Sponsor:

MedImmune LLC

Treatments:

Liraglutide